Key clinical point: Topiramate can reduce the number of headache days in a month and disability levels in children with migraine.
Major finding: Topiramate vs. placebo significantly reduced the number of migraine days in a month ( P = .0008) and migraine-related disability in pediatric patients ( P = .04), but showed no significant difference in the proportion of patients experiencing a ≥50% reduction in monthly headache days ( P = .11). Topiramate was associated with higher rates of side effects, including weight loss and paresthesia ( P less than .01 for both).
Study details: A meta-analysis of 5 randomized controlled trials, including 531 children with migraine aged 6-17 years.
Disclosures: The authors declared no conflicts of interest.
Citation: Wu X et al. Front Pediatr. 2020 Feb 27. doi: 10.3389/fped.2020.00028.